Compare Abeona Therapeutics Inc (ABEO) vs Nokia Corp (NOK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Nokia Corp — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Nokia Corp trades at $11.8 (market cap $66.24B). The key difference: Nokia Corp is far larger — about 177.4× Abeona Therapeutics Inc's market cap, and Nokia Corp pays a 1.38% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | NOK | |
|---|---|---|
Market Cap | $373.32M | $66.24B |
Sector | Health | Technology |
52-Week High | $7.23 | $16.83 |
52-Week Low | $4.17 | $4.05 |
Enterprise Value | $228.22M | $63.06B |
Dividend Yield | — | 1.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Nokia (NOK) trades at $11.85, down 1.74% amid a bearish technical signal, despite strong year-to-date performance. The company shows mixed fundamentals with a high P/E of 78.47 but recent earnings beats and a 44.12% gross margin. Recent news highlights Nokia's strategic pivot to AI infrastructure, including partnerships with Nvidia and Amazon Web Services, driving investor optimism about future growth potential in network modernization and data center markets.
Outlook remains cautiously optimistic with a consensus price target of $18.00 representing 52% upside, though high valuation and recent earnings miss pose risks. The stock's direction hinges on execution of AI initiatives and Q2 2026 earnings results due July 23, with technical indicators suggesting near-term consolidation near current support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
